Regarding anti-tumour efficacy, 8% (n=5) presented a ≥50% decline in PSA for a median duration of 86 days (56-520 days), and 8% (n=5) had PSA stabilization lasting ≥90 days. This evidence concerns the gene KLK3 and neoplasm.